Klas Petersson

Klas joined qPharmetra after finishing his PhD at Uppsala University in 2012. The main focus of his thesis was population PK/PD modeling in the disease area of schizophrenia, specifically mechanistic modeling of side effects during treatment with D2-receptor antagonists and translational aspects of predicting side effects. In addition, during his PhD he performed methodological research within the population modeling area and tutored on simulation and covariate modeling courses. In the 5+ years he has worked at qPharmetra his largest focus has been on modeling in oncology with experience in applying modeling in the full range of drug life-cycle, from pre-clinical to post-marketing. He also has experience in other therapeutic areas such as dermatology and nephrology. He holds an MSc in Pharmaceutical Bioscience from Uppsala University and is a Pharmacist by training.